Financials in USD. Standardized financial statements.
A compact view of how CStone Pharmaceuticals turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $262.63M | $407.20M | $463.84M | $481.36M | $243.72M | $1.04B | $0 | $12.55M | $10.30M | $0 |
| Revenue Growth? | -35.5% | -12.2% | -3.6% | +97.5% | -76.5% | 0.0% | -100.0% | +21.8% | 0.0% | 0.0% |
| Cost of Revenue? | $217.84M | $167.05M | $159.55M | $202.99M | $106.83M | $241.42M | $0 | $0 | $0 | $0 |
| Gross Profit? | $44.79M | $240.15M | $304.30M | $278.38M | $136.89M | $797.41M | $0 | $12.55M | $10.30M | $0 |
| Gross Margin? | +17.1% | +59.0% | +65.6% | +57.8% | +56.2% | +76.8% | 0.0% | +100.0% | +100.0% | 0.0% |
| Operating Expenses? | $466.24M | $331.85M | $884.14M | $1.19B | $1.97B | $1.89B | $1.74B | $1.04B | $242.48M | $262.17M |
| Operating Income? | -$421.46M | -$91.69M | -$579.85M | -$912.15M | -$1.83B | -$1.09B | -$1.74B | -$1.03B | -$242.48M | -$262.17M |
| EBITDA? | -$378.61M | -$26.23M | -$297.23M | -$849.66M | -$1.90B | -$1.20B | -$1.73B | -$1.02B | -$241.66M | -$262.10M |
| Income Before Tax | -$413.00M | -$91.21M | -$367.23M | -$902.68M | -$1.92B | -$1.22B | -$2.31B | -$1.79B | -$342.55M | -$253.04M |
| Income Tax Expense | $12.73M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$425.73M | -$91.21M | -$367.23M | -$902.68M | -$1.92B | -$1.22B | -$2.31B | -$1.75B | -$308.90M | -$246.09M |
| EPS? | $-0.31 | $-0.07 | $-0.29 | $-0.77 | $-1.65 | $-1.17 | $-2.39 | $-2.79 | $-0.32 | $-0.25 |
| Diluted EPS? | $-0.31 | $-0.07 | $-0.29 | $-0.77 | $-1.65 | $-1.17 | $-2.39 | $-2.79 | $-0.31 | $-0.25 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality